Results 11 to 20 of about 3,073 (139)

Simultaneous Determination of Sitagliptin Phosphate Monohydrate and Metformin Hydrochloride in Tablets by a Validated UPLC Method [PDF]

Scientia Pharmaceutica, 2012
A novel approach was used to develop and validate a rapid, specific, accurate and precise reverse phase ultra performance liquid chromatographic (UPLC) method for the simultaneous determination of Sitagliptin phosphate monohydrate and Metformin hydrochloride in pharmaceutical dosage forms.
Khagga Mukkanti
exaly   +3 more sources

NiO/CuO@Graphene oxide-modified electrode for sensitive detection of an antidiabetic drug [PDF]

Scientific Reports
A new, simple, and cost-effective electrochemical sensor was developed for the determination of Sitagliptin phosphate monohydrate (SP) in powder, pharmaceutical tablet form and biological fluids as spiked plasma.
Essam N. Labeeb, Mahmoud A. Hefnawy, Shymaa S. Medany, Eman Yossri Frag   +3 more
doaj   +2 more sources

Sitagliptin, Metformin and Glimepiride Fixed-Dose Combination Compared to Co-Administration of Metformin and High-Dose Glimepiride in Indian Patients With Type 2 Diabetes: A Randomised, Double-Blind, Double-Dummy, Phase 3 Clinical Study. [PDF]

Diabetes Obes Metab
ABSTRACT Aims This study assessed the efficacy and safety of a triple fixed‐dose combination (FDC) of sitagliptin, metformin, and glimepiride versus co‐administered metformin and glimepiride in Indian patients with uncontrolled Type 2 diabetes (T2D).
Sahay R, Gowda A, Singh MK, Rao AG, Duraisamy R, Gangwani D, Shukla J, Agarwal V, Patil SS, C A, K N SB, Palawat A, Gofne SK, Sahoo AK, Rai PK, Shaikh R, Saha S, Patil D, Ghadge P, Patel P, Lakhwani L, Mehta S, Joglekar S.   +22 more
europepmc   +2 more sources

Comparison of Serum Ketone Levels and Cardiometabolic Efficacy of Dapagliflozin versus Sitagliptin among Insulin-Treated Chinese Patients with Type 2 Diabetes Mellitus [PDF]

Diabetes & Metabolism Journal, 2022
Background Insulin-treated patients with long duration of type 2 diabetes mellitus (T2DM) are at increased risk of ketoacidosis related to sodium-glucose co-transporter 2 inhibitor (SGLT2i).
Chi-Ho Lee, Mei-Zhen Wu, David Tak-Wai Lui, Darren Shing-Hei Chan, Carol Ho-Yi Fong, Sammy Wing-Ming Shiu, Ying Wong, Alan Chun-Hong Lee, Joanne King-Yan Lam, Yu-Cho Woo, Karen Siu-Ling Lam, Kelvin Kai-Hang Yiu, Kathryn Choon-Beng Tan   +12 more
doaj   +1 more source

Therapeutic strategies for MMAE-resistant bladder cancer through DPP4 inhibition. [PDF]

Mol Oncol
We established monomethyl auristatin E (MMAE)‐resistant bladder cancer (BC) cell lines by exposure to progressively increasing concentrations of MMAE in vitro. RNA sequencing showed DPP4 expression was increased in MMAE‐resistant BC cells. Both si‐DPP4 and the DPP4 inhibitor sitagliptin suppressed the viability of MMAE‐resistant BC cells.
Li G, Tatarano S, Yoshino H, Saito S, Tominaga M, Arima J, Fukuda I, Sakaguchi T, Matsushita R, Yamada Y, Enokida H.   +10 more
europepmc   +2 more sources

Differential Expression and Enzymatic Activity of DPPIV/CD26 Affects Migration Ability of Cervical Carcinoma Cells. [PDF]

PLoS ONE, 2015
Dipeptidyl peptidase IV (DPPIV/CD26) is a transmembrane glycoprotein that inactivates or degrades some bioactive peptides and chemokines. For this reason, it regulates cell proliferation, migration and adhesion, showing its role in cancer processes. This
Aline Beckenkamp, Júlia Biz Willig, Danielle Bertodo Santana, Jéssica Nascimento, Juliano Domiraci Paccez, Luiz Fernando Zerbini, Alessandra Nejar Bruno, Diogo André Pilger, Márcia Rosângela Wink, Andréia Buffon   +9 more
doaj   +1 more source

Development of Clinically Optimized Sitagliptin and Dapagliflozin Complex Tablets: Pre-Formulation, Formulation, and Human Bioequivalence Studies

Pharmaceutics, 2023
The purpose of this study is to derive an optimal drug release formulation with human clinical bioequivalence in developing a sitagliptin phosphate monohydrate-dapagliflozin propanediol hydrate fixed-dose combination (FDC) tablet as a treatment for type ...
So-Jin Kang, Joo-Eun Kim
doaj   +1 more source

Sitagliptin attenuates arterial calcification by downregulating oxidative stress-induced receptor for advanced glycation end products in LDLR knockout mice

Scientific Reports, 2021
Diabetes is a complex disease characterized by hyperglycemia, dyslipidemia, and insulin resistance. Plasma advanced glycation end products (AGEs) activated the receptor for advanced glycation end products (RAGE) and the activation of RAGE is implicated ...
Chih-Pei Lin, Po-Hsun Huang, Chi-Yu Chen, Meng-Yu Wu, Jia-Shiong Chen, Jaw-Wen Chen, Shing-Jong Lin   +6 more
doaj   +1 more source

Acarbose Add-on Therapy in Patients with Type 2 Diabetes Mellitus with Metformin and Sitagliptin Failure: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study [PDF]

Diabetes & Metabolism Journal, 2019
BackgroundWe evaluated the efficacy and safety of acarbose add-on therapy in Korean patients with type 2 diabetes mellitus (T2DM) who are inadequately controlled with metformin and sitagliptin.MethodsA total of 165 subjects were randomized to metformin ...
Hae Kyung Yang, Seung-Hwan Lee, Juyoung Shin, Yoon-Hee Choi, Yu-Bae Ahn, Byung-Wan Lee, Eun Jung Rhee, Kyung Wan Min, Kun-Ho Yoon   +8 more
doaj   +1 more source

Sitagliptin phosphate: isolation and identification of two degradation products formed under acid conditions and determination of in vitro cytotoxicity

Drug Analytical Research, 2023
Sitagliptin phosphate (STG), used for the treatment of type 2 diabetes, is a drug that belongs to a new class called inhibitors of dipeptidyl peptidase IV (DPPIV). It is known to be the first agent of the class approved by the FDA.
Alini Dall Cortivo Lange, Diogo Miron, Le´tícia Lenz Sfair, Elfrides Eva Scherman Schapoval   +3 more
doaj   +1 more source